Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

0.7200
-0.0858-10.65%
Pre-market: 0.75000.0300+4.17%06:59 EDT
Volume:1.27M
Turnover:951.05K
Market Cap:86.12M
PE:-0.37
High:0.8300
Open:0.8200
Low:0.7200
Close:0.8058
Loading ...

Invivyd Initiated at Buy by EF Hutton

Dow Jones
·
30 Oct 2024

Invivyd Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Oct 2024

Invivyd Shares Fall After Revenue Guidance Withdrawal

MT Newswires Live
·
30 Oct 2024

BRIEF-Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, And Targets Near-Term Profitability

Reuters
·
29 Oct 2024

BRIEF-Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda (Pemivibart) Provided Substantial Protection From Symptomatic Covid-19 Versus Placebo Over Six Months Of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Reuters
·
29 Oct 2024

Invivyd announces 12-month exploratory data from CANOPY Phase 3 trial

TIPRANKS
·
29 Oct 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows Pemgarda™ (Pemivibart) Provided Substantial Protection From Symptomatic Covid-19 Versus Placebo Over Six Months of Follow-up, With No Additional Doses, in Immunocompetent Participants

THOMSON REUTERS
·
29 Oct 2024

Invivyd Inc: Targets Near-Term (1H 2025) Profitability With Existing Cash and Cash Equivalents

THOMSON REUTERS
·
29 Oct 2024

Invivyd Inc: Preliminary Q3 2024 Pemgarda™ (Pemivibart) Net Product Revenue of $9.3 Mln

THOMSON REUTERS
·
29 Oct 2024

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

THOMSON REUTERS
·
29 Oct 2024

Press Release: Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Dow Jones
·
29 Oct 2024

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

GlobeNewswire
·
29 Oct 2024

Invivyd Inc - FDA Includes Updated Viral Neutralization Data for Pemgarda

THOMSON REUTERS
·
01 Oct 2024

Invivyd Inc - FDA's Updated Statement Removes Contested Statement on Pemgarda Susceptibility

THOMSON REUTERS
·
01 Oct 2024

Invivyd Inc - Pemgarda Likely to Retain Activity Against Current Sars-Cov-2 Variants

THOMSON REUTERS
·
01 Oct 2024

Invivyd Announces U.S. FDA Has Updated the Pemgarda™ Eua Fact Sheet With Accurate Sars-Cov-2 Variant Susceptibility and Pemgarda Activity Data

THOMSON REUTERS
·
01 Oct 2024